I can see this result also giving INO a "bounce" since ONCS is using the electropolation method INO developed
I still think he will become permanent CEO--I'm sure he is "enthralled" by the potential of this company and will want to be around to see its potential fully realized (especially since we are close to the start of the scaffold trials) And Dr. Langer, Dr. Roberts and the rest of the scientific advisory board need Mr. Astrue's acumen to set up licensing and collaborative agreements with some of the "big suitors".
Why do you keep YAPPING?? you have posted multiple negative comments in the last several hours--you made your point--so SHUT-UP already--or did you forget to take your medication???
Thank you---what do you think about the chances of a major player buying out RNN--would seem to be an ideal time as the pps is so cheap
it is now being reported that there may be a conncection between Type 2 diabetes and liver cancer:
"It's not a stretch to think there might be other relationships between diabetes drugs and pancreatic or liver cancer. Diabetes is already associated with a high risk of developing pancreatic cancer."
Again Afreeza is as close to a natural insulin as there can be--easy to administer and will lead to greater treatment compliance---there is a HUGE need for something like this something the FDA had better acknowledge as the April decision approaches
Sentiment: Strong Buy
Thanks for your comment----it appears ONCS will report its melanoma treatment results (using electroporation) first (and I'm confident they will be successful)---if this is the case-then won't that have a "synergistic" effect on shares of INO since if this worked in the ONCS application there is next to "no doubt" it will work in the areas INO is focused on (prostate cancer, AML, cervical cancer etc)
if bad news what bad news? trial hasn't started-so nothing there---only thing I can think of would be the FDA not allowing the changes in the trial NVIV is asking for?
Sentiment: Strong Buy
When Mr. Astrue took over last August-it was as "interim" CEO--will the board of directors meet again soon to decide to make him full time CEO (which I hope happens)-will this wait until the human trial is up and running/partnerships established? or are they in the process of now of search for a permanent CEO
in the Globe article ("Can In Vivo turn hype into hope)-the author notes that In Vivo only has $19 million in cash to operate (which would give it about 1 more year to continue to operate)--I hope Mr. Astrue is "diligently" working behind the scenes getting some revenue generating partnerships with pharmaceutical companies to use the hydrogel/scaffold to deliver their drugs--if not could the company "fold" for lack of operating funds??
so have all the clinical results (glioblastoma/prostate cancer/DCVax-Direct etc) all part of an elaborate "scam" too?? I'm buying more on this "dip" and I'm in it for the long run
Wasn't Frank's timeline to have the trials up and running in September (fall)-and then market the scaffold by Q42014?? I don't care--I have every bit of faith that Mr. Astrue will get this going in a timely fashion especially if the changes in the trial are approved and more centres can be involved. And I still say if the scaffold trials are extremely successful (ie. neurologic improvement/recovery) how could the FDA tell a new paraplegic--"Sorry yes we do have something that can help you but it won't be available until this trial is over in 2015-2016?"
Does this change their potential groundbreaking treatments for Glioblastoma? Prostate Cancer? DCVax-Direct for solid tumors??? Take your stupid doom and gloom somewhere else!!
but don't you think a "larger player" won't step in (after reviewing NWBO's potential here) and provide the financing/royalty payments to keep the company going???
very new to this stock--invested strongly in INO/ONCS--this looks like a "homerun"--I especially like all the inside buying--obviously very confident in the results to follow---should I sell at least some of my positions in those companies to load up on NWBO--and is there a strong likelihood this will be the next ONYX???
ONCS is utilizing a method called "electropolation" to allow drugs/vaccines to enter melanoma cells directly without all the nasty side effects seen with conventional treatments--they are about to report results of their resent trials (I believe Phase 2)--there earlier results have been remarkable in stage III melanoma--I see them as a target for a bigger player (?Roche etc)
I have a little money to invest--what will give the "bigger bang" for the buck---NWBO or Oncosec (ONCS) which I've read could revolutionize melanoma treatment??